FDA observations ‘primarily procedural’ –

ciplaUSFDA issued four observations about Cipla’s manufacturing facilities in Goa after conducting an audit, the company said. Cipla has three facilities in Goa.

“The observations were primarily procedural in nature and the company has already responded to these observations,” said the pharma company. Further details were not given.

The company said it will continue to operate their facilities with high level of compliance and control.

Cipla Limited, founded in 193, is an Indian multinational pharmaceutical and biotechnology company, headquartered in Mumbai.

Cipla has 34 manufacturing units in 8 locations across India and has presence in 100 countries.